Clinical trials: Overweight and/or Obesity
Type 2 Diabetes Mellitus Combined With Overweight or Obesity
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250…
- Trial name
- NCT07747857
- Testing
- TQF3250 capsules
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity / Overweight
A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.
This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.
- Trial name
- NCT07794111
- Testing
- TQF6422 Injection
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Overweight or Obesity
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
- Trial name
- NCT06396429
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 1 Diabetes (T1D), Overweight
A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity
The purpose of this clinical study is to find out if NNC0497-0040 is safe, tolerable and effective for healthy people living with normal weight or overweight, people living with overweight or obesity and people who have type 1…
- Conditions
- Type 1 Diabetes (T1D), Overweight, Obesity, Healthy Volunteers
- Trial name
- NCT07578584
- Testing
- NNC0497-0040
- Where
- Germany
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Healthy, Obesity
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or…
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07407348
- Testing
- Formulation A, Formulation B6
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity
A Study of ZT002 Injection With Subjects With Overweight or Obesity
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
- Trial name
- NCT07020884
- Testing
- ZT002 Injection
- Where
- 16 sites in China
- Volunteers
- 303 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide.
- Trial name
- NCT06388187
- Testing
- Cagrilintide, Semaglutide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity
Probiotic Influence on Obesity-Related Lipidemia
This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults.
- Trial name
- NCT06305650
- Testing
- Probiotic
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Obesity
The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo.
- Trial name
- NCT03364335
- Testing
- Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg
- Where
- 15 sites in United States
- Volunteers
- 267 people
- Sponsor
- NuSirt Biopharma
Overweight, Obesity
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle modification…
- Conditions
- Overweight, Obesity, Overweight and Obesity, Overweight or Obesity
- Trial name
- NCT04110717
- Testing
- Vestal Device, Control Device, Hypocaloric Diet
- Where
- Ireland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Overweight
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine.
- Trial name
- NCT06719011
- Testing
- NNC0174-1213 A, Cagrilintide B
- Where
- 2 sites in United States
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07684144
- Testing
- Maridebart Cafraglutide
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 950 people
- Sponsor
- Amgen
Overweight or Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.
- Trial name
- NCT06762600
- Testing
- HRS-4729 injection, HRS9531 injection, Acetaminophen
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Hypertension
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
- Trial name
- NCT06952530
- Testing
- Orforglipron
- Where
- 99 sites in United States, Argentina and 9 more
- Volunteers
- 487 people
- Sponsor
- Eli Lilly and Company
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S